The Gulf War Synergy Trial is currently enrolling participants for a promising new treatment for Gulf War Illness (GWI). This 20-week clinical trial will study the use of a low dose stimulant medication (Ritalin®) in combination with a potent mitochondrial support nutrient formula designed to improve mitochondrial functioning. Mitochondrial dysfunction has recently drawn attention as a potential cause of Gulf War Illness.
The symptoms of Gulf War Illness (GWI) are extremely similar to those of CFS. In fact, research has shown that individuals with GWI are diagnosed with CFS at an incidence of 40 times greater than the general population. Due to a high level of toxic exposure coupled with the stress of war, veterans returning to U.S. with symptoms of GWI may, in fact, have developed CFS at an accelerated rate.
Since this treatment has already been shown to lessen fatigue symptoms in people with CFS, it is possible it can improve the chronic fatigue and cognitive deficits experienced by veterans with GWI
“The classic presentation for mitochondrial illness involves multiple symptoms spanning many domains, similar to what we see in Gulf War illness,” stated Beatrice Golomb, MD, a professor and researcher at UC San Diego medical school. “These include fatigue, cognitive and other brain-related challenges, muscle problems and exercise intolerance, with neurological and gastrointestinal problems also common.”
Golomb has published a study showing that antioxidant supplementation helped to decrease symptoms of fatigue and cognitive dysfunction in patients with GWI.
The nutrient formula used in the GWI Synergy Trial contains these antioxidants as well as other nutrients known to enhance the mitochondrial functioning and improve the health of the nervous, endocrine, and immune systems.
The GWI Synergy Trial will enroll 30 patients during 2016 at the Palo Alto VA Health Center to evaluate the safety and efficacy of this combination treatment. Male and female participants between the ages of 18 and 64 who meet the Kansas Case Definition for GWI are encouraged to contact the Palo Alto VA site coordinator at (650) 493-5000, ext. 62219 to determine if they are eligible to participate. Participants will receive comprehensive medical exams and compensation.
This trial is being sponsored by K-PAX Pharmaceuticals and the U.S. Department of Defense.